Straits Times Index
3,318.45 +1.89 (+0.06%) S&P 500
5,304.72 +36.88 (+0.70%) Dow
39,069.59 +4.29 (+0.01%) Nasdaq
16,920.79 +184.79 (+1.10%) Bitcoin USD
69,887.77 +1,046.74 (+1.52%) CMC Crypto 200
1,507.65 +23.45 (+1.58%)
Teva Pharmaceutical Industries Limited (TEVA.TA)
| Previous close | 6,102.00 |
| Open | 6,071.00 |
| Bid | 6,087.00 x 200 |
| Ask | 6,088.00 x 34100 |
| Day's range | 6,080.00 - 6,129.00 |
| 52-week range | 2,637.00 - 6,297.00 |
| Volume | |
| Avg. volume | 1,429,068 |
| Market cap | 69.87B |
| Beta (5Y monthly) | 1.05 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.54 |
| Earnings date | 31 Jul 2024 - 05 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 28 Nov 2017 |
| 1y target est | 14.86 |
Business WireTeva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.
PARSIPPANY, N.J. & REYKJAVÍK, Iceland, May 21, 2024--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Alvotech (NASDAQ: ALVO), today announced the availability of SIMLANDI (adalimumab-ryvk) injection in the U.S., as an interchangeable biosimilar to Humira for the treatment of adult rheumatoid arthritis, juvenile idiopathic arthritis, adult psoriatic arthritis, adult ankylosing spondylitis, Crohn’s disease, adult ulcerative colitis, adult pla
GuruFocus.comInsider Sale: Chief Accounting Officer Amir Weiss Sells 28,135 Shares of Teva Pharmaceutical ...
On May 16, 2024, Amir Weiss, the Chief Accounting Officer of Teva Pharmaceutical Industries Ltd (NYSE:TEVA), executed a sale of 28,135 shares of the company.
Business WireTeva Announces Appointment of Matthew Shields to Executive Vice President, Teva Global Operations
TEL AVIV, Israel, May 15, 2024--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the appointment of Matthew Shields as Executive Vice President of Teva Global Operations (TGO), the Company’s manufacturing and supply division, effective June 3, 2024. Mr. Shields succeeds Eric Drapé, who is leaving after 11 years with the Company, including more than four years as Executive Vice President, Global Operations. Mr. Shields will be a member of Teva’s Executive Leadership Team
